Research peptides are short chains of amino acids sold primarily by vendors like a peptide supplier for research use marketed for laboratory investigation rather than human consumption. Despite that labeling, many buyers are biohackers, athletes, or individuals seeking alternatives to prescription therapies, drawn by claims of muscle growth, fat loss, anti-aging effects, and cognitive enhancement. In Canada and most jurisdictions, these compounds occupy a legal gray zone: they’re not approved drugs, yet selling them “for research only” sidesteps therapeutic goods regulation, leaving…
Right to Try and Psychedelics: What Patients Can—and Can’t—Access in 2026
The Right to Try Act offers a federal pathway for patients with life-threatening illnesses to access investigational drugs outside clinical trials, but using it to obtain psychedelic therapies like psilocybin or MDMA remains legally complex and practically difficult. While the 2018 law allows patients who have exhausted approved treatments to request experimental medicines directly from manufacturers, it does not compel any company to say yes, and most psychedelic developers have been reluctant to supply therapies outside controlled research settings.
On April 18, 2026, President Trump signed an executive order directing the FDA and…